Longevity Science — 2026-09-15
Semaglutide (Ozempic) has been shown to slow biological aging and extend lifespan in healthy older mice, suggesting GLP-1 drugs may activate longevity pathways independent of weight loss. Meanwhile, the longevity biotech sector continues to attract significant capital, with recent developments including Moonwalk's $70M raise for RNAi therapies and Science Corp's $230M funding for vision restoration.
Longevity Science — 2026-09-15
Top Research Findings
Semaglutide Extends Lifespan in Healthy Mice A new study published via ScienceDaily reveals that semaglutide, the active ingredient in Ozempic, helped older healthy mice live longer while improving memory, muscle function, and blood sugar control. The drug’s effects went beyond those seen with calorie restriction, raising the possibility that GLP-1 receptor agonists could tap into a separate biological pathway for longevity. This suggests that the anti-aging benefits of these drugs may be distinct from their metabolic effects.
Proteomic Aging Clocks Validated in Clinical Trials A study in Nature Biotechnology demonstrated the integration of proteomic aging clocks in a phase 2a clinical trial to support simultaneous geroprotective assessment. Researchers used the Olink Explore 3072 platform to obtain longitudinal proteomic profiles from serum samples, analyzing them via multi-clock monitoring of aging rates. This validates a new method for measuring biological age changes in real-time during intervention trials, offering more precise data on whether a drug is actually slowing aging at the molecular level.
sciencedaily.com
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments | Signal
Nature Aging
The pursuit of understanding human longevity | npj Aging
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotect
Clinical Trials & Intervention Updates
Serina Therapeutics Advances Parkinson’s Trial Serina Therapeutics has advanced its SER-252 Parkinson’s disease trial to a second cohort following a successful safety review. While primarily a neurodegenerative focus, this trial contributes to the broader understanding of cellular senescence and neuroprotection, key pillars of longevity science. The progression to a second cohort indicates positive initial safety data, a critical step for interventions targeting age-related brain decline.
Resolution Therapeutics Completes Liver Disease Trial Enrollment Resolution Therapeutics has completed enrollment for its cell therapy trial targeting severe liver disease. Cell therapies are increasingly viewed through a longevity lens as they aim to regenerate tissue rather than just manage symptoms. The completion of enrollment marks a transition toward efficacy data, which will be closely watched by the longevity community for insights into regenerative capacity in aged tissues.
Industry & Biotech Watch
Moonwalk Raises $70M for Adipose-Targeted RNAi Moonwalk, a biotech startup, has raised $70 million to develop adipose-targeted RNA interference (RNAi) therapies. This funding round highlights the growing investor interest in targeting specific tissue types for metabolic and aging-related interventions. RNAi technology allows for precise gene silencing, offering potential for treating obesity-related inflammation and other drivers of accelerated aging.
Science Corp Lands $230M for Vision Restoration Science Corp secured $230 million to commercialize its vision restoration chip. While focused on blindness, this massive funding round reflects the broader trend of high-value investments in "bio-hacking" and restorative technologies. Success here could accelerate the regulatory pathway for other implantable longevity devices and neural interfaces.
Deep Dive: Intervention Evidence Check
Rapamycin: Mechanism Clarified, Human Data Pending Rapamycin remains a top contender in longevity science. Recent mechanistic data from Kell and colleagues provides a cellular explanation for its effects, showing reduced senescence rather than immune suppression at low intermittent doses. This distinction is central to the longevity hypothesis, differentiating it from the immunosuppressive effects seen at continuous high doses used in transplant medicine. However, while preclinical data is strong, large-scale human trials are still ongoing to confirm safety and efficacy for healthy adults.
What to Watch Next
- NKGen Biotech Alzheimer’s Data: NKGen Biotech is set to present Alzheimer’s and brain disease trial data at an upcoming Korea summit, which may provide insights into gene therapy approaches for neurodegeneration.
- FDA Review of Nanoscope Gene Therapy: The FDA has accepted a review for Nanoscope’s one-time vision loss gene therapy. A positive decision could set precedents for single-dose genetic interventions for age-related conditions.
- Apple Watch "Health Age" Metrics: Apple Watch can now estimate your ‘health age’ using AI. Widespread adoption of this feature could democratize biological age tracking, providing more real-world data on how lifestyle interventions affect aging markers.
Reader Action Items
- Discuss GLP-1s with Your Doctor: If you have metabolic issues, discuss the emerging evidence that GLP-1 drugs like semaglutide may offer longevity benefits beyond weight loss, potentially protecting brain and muscle health.
- Monitor Biological Age: Explore tools like the new Apple Watch health age estimate or blood-based proteomic clocks to track your biological age trends over time, especially if you are implementing lifestyle or supplement interventions.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
